Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical Inc. is demonstrating a strong financial outlook, with projected EBITDA increasing from $24.4 million at a 16.8% margin in FY26 to $27.3 million at a 19.1% margin in FY27, indicating significant improvement in operational efficiency. Furthermore, free cash flow (FCF) has turned positive, with expectations of growing from $5.1 million in FY26 to $6.0 million in FY27, reflecting the company's ability to generate cash after capital expenditures. These key metrics suggest strong revenue growth and enhancing profitability, supporting a favorable outlook for the company's stock.

Bears say

Lifecore Biomedical's outlook is negatively impacted by its anticipated slow revenue growth, with projections indicating no meaningful increases until calendar year 2027. The company is also facing a high leverage ratio, which contributes to concerns over its financial stability and warrants a discount compared to industry peers. Additionally, while the company expects a 10% market growth figure in fill/finish services, this rate is considered optimistic given a projected market decline influenced by the inclusion of small molecule injectables.

LFCR has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Hold based on their latest research and market trends.

According to 1 analysts, LFCR has a Hold consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.